311 top medical experts on Mucopolysaccharidosis II across 42 countries and 24 U.S. states, including 133 MDs (Physicians). This is based on an objective analysis of their Scientific Publications, Clinical Trials, Medicare, and NIH Grants.

  1. Mucopolysaccharidosis II: Systemic lysosomal storage disease marked by progressive physical deterioration and caused by a deficiency of L-sulfoiduronate sulfatase. This disease differs from mucopolysaccharidosis I by slower progression, lack of corneal clouding, and X-linked rather than autosomal recessive inheritance. The mild form produces near-normal intelligence and life span. The severe form usually causes death by age 15.
  2. Clinical guidelines are the recommended starting point to understand initial steps and current protocols in any disease or procedure:
  3. Broader Categories (#Experts): Mucopolysaccharidoses (1,530), X-Linked Mental Retardation (2,803).
  4. Clinical Trials ClinicalTrials.gov : at least 58 including 7 Active, 26 Completed, 15 Recruiting
  5. Synonyms: Hunter Syndrome Gargoylism,  Hunter's Syndrome,  Iduronate 2-Sulfatase Deficiency,  Iduronate Sulfatase Deficiency,  Sulfoiduronate Sulfatase Deficiency


  

        

                    


    Computing Expert Listing ...

);